LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Ouvert

SecteurSoins de santé

2.08 -3.26

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.08

Max

2.25

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+305.12% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-96M 690M
Ouverture précédente	5.34
Clôture précédente	2.08

Sentiment de l'Actualité

By Acuity

50%

153 / 344 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juin 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 juin 2026, 23:38 UTC

Acquisitions, Fusions, Rachats

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 juin 2026, 22:08 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 juin 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 juin 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 juin 2026, 21:22 UTC

Market Talk

Acquisitions, Fusions, Rachats

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 juin 2026, 20:46 UTC

Acquisitions, Fusions, Rachats

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 juin 2026, 20:22 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares $11 Special Div

1 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 juin 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 juin 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 juin 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 juin 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 juin 2026, 18:54 UTC

Acquisitions, Fusions, Rachats

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 juin 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 juin 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 juin 2026, 18:00 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 juin 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 juin 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 17:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

305.12% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 305.12%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

153 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.